{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-DDYAGSUD/08a25110-d5a9-4313-9be1-2d89a359b72b/PDF","dcterms:extent":"1031 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-DDYAGSUD/2ef8c0a6-d93c-4ec8-8e6a-f64c1467f3d7/TEXT","dcterms:extent":"47 KB"}],"edm:TimeSpan":{"@rdf:about":"2005-2025","edm:begin":{"@xml:lang":"en","#text":"2005"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-DDYAGSUD","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN"},{"@xml:lang":"sl","#text":"Farmacevtski vestnik"}],"dcterms:issued":"2022","dc:creator":"Morgan, Tina","dc:format":[{"@xml:lang":"sl","#text":"številka:2"},{"@xml:lang":"sl","#text":"letnik:73"},{"@xml:lang":"sl","#text":"str. 95-106"}],"dc:identifier":["COBISSID_HOST:140694275","ISSN:2536-4316","URN:URN:NBN:SI:doc-DDYAGSUD"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"dc:subject":[{"@xml:lang":"en","#text":"anti-inflammatory medications"},{"@xml:lang":"en","#text":"antiviral medications"},{"@xml:lang":"sl","#text":"Covid-19"},{"@xml:lang":"sl","#text":"Protivirusna zdravila"},{"@xml:lang":"sl","#text":"Protivnetna zdravila"},{"@xml:lang":"sl","#text":"SARS-CoV (virus)"},{"@xml:lang":"en","#text":"SARS-CoV-2"},{"@xml:lang":"sl","#text":"Terapija z zdravili"}],"dcterms:temporal":{"@rdf:resource":"2005-2025"},"dc:title":{"@xml:lang":"sl","#text":"Zdravljenje koronavirusne bolezni 19 z zdravili| Overview of COVID-19 therapeutics|"},"dc:description":[{"@xml:lang":"sl","#text":"The underlying pathophysiologic evolution of the disease from the predominantly viral infection-driven phase to the late, immune-mediated phase is important in the assessment of the role of medications against COVID-19. The best results can be expected from the orally used nirmatrelvir coformulated with ritonavir, the intravenously used remdesivir and the anti-SARS-CoV-2 monoclonal antibodies. The oral antiviral molnupiravir is less effective. When treating the fully developed disease, the most widely tested medications are dexamethasone and tocilizumab. Other anti-inflammatory treatments, baricitinib, tofacitinib or anakinra, have been shown to express very good clinical endpoints, which were however proven in a single clinical trial. The virus mutating to a variant less likely to cause typical presentation with severe immunological derangements probably will prevent us from gaining further knowledge in this area of therapeutics"},{"@xml:lang":"sl","#text":"Za razumevanje vloge zdravil za zdravljenje koronavirusne bolezni 19 je pomembno poznati patofiziološko osnovo delitve na zgodnjo fazo bolezni, ko zamejujemo širjenje virusne okužbe, in pozno fazo, ko ugodne izide dosežemo z blaženjem vnetja. Najuspešnejše protivirusne učinkovine so peroralni nirmatrelvir z ritonavirjem ter remdesivir in monoklonska protitelesa proti SARS-CoV-2 za parenteralno uporabo, peroralni molnupiravir pa je manj učinkovit. Najširše preskušeni protivnetni učinkovini sta deksametazon in zaviralec IL-6 tocilizumab. Druge protivnetne učinkovine, baricitinib oz. tofacitinib in anakinra, izkazujejo zelo dobre klinične izide, vendar dokazane le v eni raziskavi. Mutacija virusa v obliko, ki redko povzroča nebrzdano vnetje, pomeni, da verjetno ne bomo dočakali novih uporabnih izidov velikih raziskav na tem področju"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-DDYAGSUD","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-DDYAGSUD"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-DDYAGSUD/08a25110-d5a9-4313-9be1-2d89a359b72b/PDF"},"edm:rights":{"@rdf:resource":"http://rightsstatements.org/vocab/InC/1.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-DDYAGSUD/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-DDYAGSUD"}}}}